HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Supplement Firm Warnings Up, Enforcement Tools Idle, Hemp and NAC Still In Limbo

Executive Summary

FDA “didn’t really take any steps towards a resolution” in 2021 and is “mostly content” with enforcement discretion allowing sales of non-drug products which contain cannabinoids and other hemp-derive ingredients, says Stuart Pape, of Polsinelli PC, during a recent Food and Drug Law Institute conference.

You may also be interested in...

Honey Nasal Spray Recall Plus FDA Investigation Adds Up To California Firm Closing Up Shop

FDA inspection seven months after NDAL Manufacturing announced recall of Manukaguard Allercleanse nasal spray with manuka honey found firm’s compliance with GMP regulations left room for contaminants to reach its products. Violative drug claims and mislabeled supplements also found.

US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate

Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.

NAC Gains Tentative Safety Clearance As US Industry Contests FDA's Attempt To Remove It

FDA answers reach supplement industry sounding like a siren that the agency may take same enforcement step it has with NAC with other ingredients long used in supplements. Answers also might not be enough to convince firms to return NAC-containing supplements to their lineups.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts